Colonics
About Me
Recent Posts
- New Journal Emphasizes Principles Of Injury, Function And Rehabilitation
- Pregnancy and fertility following bariatric surgery
- Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges
- Home-based program to improve exercise and diet improves senior cancer survivors' physical function
- New Cause Of Fatal Brain Injury From Acute Viral Meningitis Discovered By Scripps Research Scientists
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
Friends
Links
Entry 1 of 437
Last Page | Next Page
2/19/2008
-
MabCampath Available For First Line Treatment Of B-Cell Chronic Lymphocytic Leukaemia (CLL) For Whom Fludarabine Chemotherapy Is Not Appropriate
|
Bayer Schering Pharma (BSP) and Genzyme Corporation, keep quiet the availability of MabCampath® (alemtuzuma More: - Read the rest here
Technorati Tags: fludarabine, for the, mabcampath, treatment
Filed under: fludarabine, for the, mabcampath, treatment |
Post A Comment! :: Send to a Friend! |
for the first-line treatment of career with B-CLL for whom fludarabine combination chemotherapy is not appropriate.[i] MabCampath was long ago approved for the treatment of B-CLL in chosen work who have been already treated with alkylating agents and have failed fludarabine therapy.Share and enjoy
